Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

city in males at drug exposures between 2-7 times that of human exposure at 80 mg/day (doses in rats were 5, 30 and 180 mg/kg/day).

An increased incidence of thyroid neoplasms in rats appears to be a response that has been seen with other HMG-CoA reductase inhibitors.

A chemically similar drug in this class was administered to mice for 72 weeks at 25, 100, and 400 mg/kg body weight, which resulted in mean serum drug levels approximately 3, 15, and 33 times higher than the mean human serum drug concentration (as total inhibitory activity) after a 40 mg oral dose. Liver carcinomas were significantly increased in high dose females and mid- and high dose males, with a maximum incidence of 90 percent in males. The incidence of adenomas of the liver was significantly increased in mid- and high dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high dose mice than in controls.

No evidence of mutagenicity was observed in a microbial mutagen test using mutant strains of Salmonella typhimurium with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an in vitro alkaline elution assay using rat or mouse hepatocytes, a V-79 mammalian cell forward mutation study, an in vitro chromosome aberration study in CHO cells, or an in vivo chromosomal aberration assay in mouse bone marrow.

Drug-related testicular atrophy, decreased spermatogenesis, spermatocytic degeneration and giant cell formation were seen in dogs starting at 20 mg/kg/day. Similar findings were seen with another drug in this class. No drug-related effects on fertility were found in studies with lovastatin in rats. However, in studies with a similar drug in this class, there was decreased fertility in male rats treated for 34 weeks at 25 mg/kg body weight,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Boston, MA (PRWEB) , ... July 28, 2015 , ... ... developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but ... One thing individuals can do is to take part in a clinical trial, reports ...
(Date:7/28/2015)... ... July 28, 2015 , ... The ... Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation ... individuals with active yet undetected sub-clinical disease, who are at risk of experiencing ...
(Date:7/28/2015)... ... July 28, 2015 , ... For more than two ... based its selection process on the foundation of peer nominations. Physicians nominate other ... any area of medicine and in any part of the country. Physicians cannot ...
(Date:7/28/2015)... ... July 28, 2015 , ... One ... including Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression ... Designed by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include ...
(Date:7/28/2015)... ... , ... Nurses across all settings increasingly provide care to people with mental ... mental health services (SAMHSA, 2013) and the implementation of the Affordable Care Act is ... the largest workforces who provide care to persons with mental health disorders. Providing this ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... being circulated in South Asia for various ailments like malaria, ... a British doctor in Laotian capital, Vientiane, the drugs have ... find out. ,World Health Organization states that majority ... been treated with the original drug. They also add that ...
... the makers of ADHD drugs to indicate the contra indications ... cardiovascular risks. ,Dr. Steven Galson, director of the ... these drugs are immensely useful in treating patients with ADHD, ... He also said that FDA is working in tandem ...
... of your wedding celebration. The world-renowned research and care center ... save lives of cancer patients. Couples getting married are encouraged ... Jimmy Fund. Dana-Farber treats both children and adults, and is ... ,A package of 10 table cards, gift cards, or ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Mukesh Haikerwal, today congratulated the Victorian Government on introducing ... child carers are trained in handling potentially deadly severe ... anaphylaxis program to be implemented nationally. ... to protect the children who suffer from severe allergies, ...
... who become impotent after prostate cancer surgery may find reprieve ... penis,// which assists in restoring the lost erectile function, according ... came to light after a study of nearly 44 patient ... function, following its loss after treatment for prostate cancer. ...
Cached Medicine News:Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:National Plan Needed for Severe Allergy Kids 2
(Date:7/28/2015)... July 28, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Human Insulin Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778) Explore more about Global ...
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... flexible and portable clinical molecular diagnostic system designed ... Care market.  At just 9 inches tall, and ... run the same high quality PCR-based Xpert® cartridges ... highly accurate clinical molecular diagnostic tests to be ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announce that it has received final approval for its common ... Stock Exchange (the "TSX"). The Company,s common shares will commence ... 2015 under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares ... About ESSA Pharma Inc. ESSA Pharma is ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... (NASDAQ: MASI ) today announced that in line ... Cost of Care by Taking Noninvasive Monitoring to New Sites ... (SpHb®) will further the company,s stated mission,  Masimo is introducing ... ransfusion R elated C ost R eduction ...
... JAZZ ) today announced that the company will host ... 2011 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, ... quarter and full year 2011 financial results. The ... Investors section of the Jazz Pharmaceuticals, website at www.jazzpharmaceuticals.com ...
Cached Medicine Technology:Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 2Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 3Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 4Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 5Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 6Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 7
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: